Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort

BACKGROUND: Tumor mutation burden (TMB) is a biomarker frequently reported by clinical laboratories, which is derived by quantifying of the number of single nucleotide or indel variants (mutations) identified by next-generation sequencing of tumors. TMB values can inform prognosis or predict the res...

Descripción completa

Detalles Bibliográficos
Autores principales: Bevins, Nicholas, Sun, Shulei, Gaieb, Zied, Thorson, John A, Murray, Sarah S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174068/
https://www.ncbi.nlm.nih.gov/pubmed/32217764
http://dx.doi.org/10.1136/jitc-2020-000613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174068/
https://www.ncbi.nlm.nih.gov/pubmed/32217764
http://dx.doi.org/10.1136/jitc-2020-000613

Ejemplares similares